Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SHE:300937)
China
· Delayed Price · Currency is CNY 31.54
-0.40 (-1.25%)
At close: Mar 9, 2026
SHE:300937 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Net Income | -5.93 | 16.36 | 59.53 | 42.02 | 6.4 | 54.02 | Upgrade
|
| Depreciation & Amortization | 29.77 | 29.77 | 24.37 | 23.85 | 16.57 | 10.04 | Upgrade
|
| Other Amortization | 10.08 | 10.08 | 6.12 | 3.06 | 1.92 | 1.4 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.61 | 0.61 | 0.05 | 0.08 | 0.11 | 0.06 | Upgrade
|
| Asset Writedown & Restructuring Costs | -0.4 | -0.4 | 0.01 | 20.14 | 6.46 | 5.72 | Upgrade
|
| Loss (Gain) From Sale of Investments | 1.84 | 1.84 | -1.54 | 4.29 | -7.52 | -0.18 | Upgrade
|
| Provision & Write-off of Bad Debts | 6.04 | 6.04 | 9.89 | - | - | - | Upgrade
|
| Other Operating Activities | -109.9 | 20.29 | 19.46 | 0.48 | 2.15 | 0.22 | Upgrade
|
| Change in Accounts Receivable | -2.48 | -2.48 | -30.26 | -18.43 | -73.83 | -49.33 | Upgrade
|
| Change in Inventory | 34.77 | 34.77 | -117.3 | 18.95 | -133.44 | -45.63 | Upgrade
|
| Change in Accounts Payable | 21.06 | 21.06 | -79.43 | 62.6 | 28.88 | 93.82 | Upgrade
|
| Operating Cash Flow | -24.78 | 127.69 | -115.47 | 152.67 | -154.38 | 69.32 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | - | 63.74% | Upgrade
|
| Capital Expenditures | -21.13 | -32.21 | -35.33 | -18.32 | -31.43 | -35.22 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.95 | 0.67 | 0.54 | 0.08 | 0.01 | 6.33 | Upgrade
|
| Cash Acquisitions | -0.09 | -0.09 | 0.07 | 20.89 | - | -0.08 | Upgrade
|
| Divestitures | - | 1.1 | 3.03 | 0.33 | -0.09 | - | Upgrade
|
| Investment in Securities | -22.11 | -19.73 | -7.72 | -13.68 | -100.62 | -2.39 | Upgrade
|
| Other Investing Activities | 0.67 | 0.65 | -95.64 | 0.32 | 0.19 | 0.63 | Upgrade
|
| Investing Cash Flow | -41.71 | -49.62 | -135.04 | -10.39 | -131.93 | -30.72 | Upgrade
|
| Short-Term Debt Issued | - | 457.5 | 330.5 | 185.42 | 130.2 | 40.05 | Upgrade
|
| Total Debt Issued | 424.58 | 457.5 | 330.5 | 185.42 | 130.2 | 40.05 | Upgrade
|
| Short-Term Debt Repaid | - | -454 | -195.42 | -119.2 | -51 | -40 | Upgrade
|
| Long-Term Debt Repaid | - | -8.42 | -6.26 | -5.88 | -3.79 | - | Upgrade
|
| Total Debt Repaid | -367.22 | -462.42 | -201.68 | -125.08 | -54.79 | -40 | Upgrade
|
| Net Debt Issued (Repaid) | 57.35 | -4.92 | 128.82 | 60.34 | 75.41 | 0.05 | Upgrade
|
| Common Dividends Paid | -16.48 | -30.25 | -24.12 | -5.31 | -20.67 | -12.64 | Upgrade
|
| Other Financing Activities | -7.99 | 0.3 | 2.71 | 2.16 | 272.06 | 0.25 | Upgrade
|
| Financing Cash Flow | 32.88 | -34.88 | 107.42 | 57.18 | 326.8 | -12.34 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0 | 0 | -0 | -0 | - | - | Upgrade
|
| Net Cash Flow | -33.61 | 43.2 | -143.1 | 199.47 | 40.49 | 26.25 | Upgrade
|
| Free Cash Flow | -45.91 | 95.48 | -150.8 | 134.35 | -185.81 | 34.1 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | - | 479.04% | Upgrade
|
| Free Cash Flow Margin | -1.05% | 2.18% | -3.40% | 3.38% | -5.46% | 1.22% | Upgrade
|
| Free Cash Flow Per Share | -0.48 | 0.99 | -1.57 | 1.41 | -2.03 | 0.47 | Upgrade
|
| Cash Income Tax Paid | 70.55 | 58 | 65.36 | 44.38 | 30.78 | 41.66 | Upgrade
|
| Levered Free Cash Flow | 64.27 | 5.51 | -195.93 | 177.55 | -201.21 | -0.94 | Upgrade
|
| Unlevered Free Cash Flow | 69.62 | 11.58 | -191.82 | 181.57 | -200.07 | 0.2 | Upgrade
|
| Change in Working Capital | 43.13 | 43.13 | -233.37 | 58.74 | -180.48 | -1.97 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.